Sanofi India Faces ₹1.43 Cr Tax Demand Routine Challenge for Pharma Giant

Demand Context

This latest notice follows a pattern of tax litigations in the pharmaceutical sector, often related to transfer pricing, deductions, or assessment disputes. Sanofi, a key player in vaccines and specialty drugs, maintains robust compliance but contests such orders through appellate channels, as seen with peers like SRF's recent wins.
​
Key Highlights

• Demand Value: ₹14.3 million total; specifics on assessment year undisclosed in initial filing.
• ​Company Stance: Will assess merits and pursue appeals; no expected material impact on finances.
• ​Sector Trend: Pharma firms face frequent scrutiny; Sanofi joins SRF (₹157.6 Cr demand) in routine disclosures.
• ​Business Resilience: Q2FY26 revenue up 12% YoY; focus on immunology portfolio amid India growth.

​
Investor Perspective
Negligible hit; stock stable with dividend yield appeal in defensive pharma space.

Sources: Marketscreener/Reuters, BSE Disclosures